Amendment to CSSB 6, Section 1.45, page 60, line 16                          
		(5)  development of protocols for use pyschotropic 
medications for foster children based on the recommendations and 
best practices manual developed by an ad hoc work group consisting 
of experts from the fields of pharmacy, psychiatry, pediatrics, 
family practice, and internal medicine and staff from the 
commission. 
	Is amended to read:                                                            
	No ad hoc working group, or other group or team set up to 
develop protocols for the use of psychotropic medications in foster 
children shall receive donations, gifts, or other funding from 
pharmaceutical companies or other groups who could be understood to 
have a financial stake in the use of such medications. No member of 
any team for developing psychotropic drug protocols shall have:
	(a)  a history of employment by a pharmaceutical company in 
the past three years;
	(b)  a financial interest in a pharmaceutical company;                  
	(c)  or shall have conducted studies, clinical trials, or 
other activities funded by a pharmaceutical company for at least 
three years.